Clinical trial
Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer…
NCT00256932 · Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry · Completed
Key facts
| NCT number | NCT00256932 |
|---|---|
| Title | Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Alvimopan 0.5mg Once Daily and 0.5mg Twice Daily for 12 Weeks for the Treatment of Opioid-Induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain |
| Lead sponsor | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Industry |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bowel Dysfunction, Constipation |
| Intervention type | Drug |
| Interventions | alvimopan, Placebo |
| Enrollment | 518 |
| Start date | Aug 1, 2005 |
| Completion | May 1, 2006 |
| First posted | Nov 22, 2005 |
| Last update posted | Sep 2, 2015 |
| Countries | Austria, Canada, Denmark, Estonia, Finland, Germany, Ireland, Poland, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: